Best Diabetes Companies in Israel
The 35 best Diabetes companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BiomX.
- Insulin Pumps Market Growth 2022-2028: The Growing Prevalence of Diabe
Ranked: Best Diabetes companies in Israel
| # | Company | Last round | Disclosed funding | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANATech Nuclear Magnetic Resonance Technologies for Non-invasive blood glucose monitoring | — | — | Unfunded | — | Gil Keini Founder & CEO | — | — | — |
| 2 | CureSound Developer of non-invasive device to manage pain | — | — | Unfunded | — | Motti Oderberg CEO | — | — | — |
| 3 | Diabotanical Plant-extract as drugs for diabetes | — | — | Deadpooled | — | Vitaly Vishnepolsky Founder & CEO | — | — | — |
| 4 | Digma Medical Non-invasive medical device for diabetes | — | — | Funding Raised | 14 | Avia Herschkovitz Co-Founder | — | 45 patents Gastrointestinal neural ablation and submucosal modulation devices for organ function control | — |
| 5 | EasyNotes Medical Developer of endoscopic procedure for the treatment of type 2 diabetes | — | — | Deadpooled | — | Fabian Izhak Co-Founder & CEO | — | — | — |
| 6 | epitomee medical Epitomee Medical is a drug-free, self-administered shapeshifting capsule, for inducing weight loss and… | — | — | Public | 38 | Shimon Eckhouse Co-Founder & Chairman | Top 50M | 36 patents Controllable self‑expanding ingestible devices for gastric therapy that disintegrate on demand | — |
| 7 | GlucoCheck Developing pain-free glucose monitoring solutions | — | — | Deadpooled | — | Adi Kahn Founder | — | 5 patents Miniaturized blood sampling devices for point‑of‑care glucose testing | — |
| 8 | GlucoMe Wireless Blood Glucose Monitor | — | — | Funding Raised | — | — | — | 14 patents Portable glucose monitoring devices and integrated medical data collection/analysis systems. | — |
Top 12 Diabetes companies in Israel
#1
Public · Ness Ziona, Center District · founded 2015 · 65 employees$56Mraised▾
Microbiome therapeutics for diseases associated with microbiome dysbiosis. The company offers its flagship 3-tier microbiome modulation platform which is an end-to-end platform to identify target bacteria causing microbiome dysbiosis, modulate the microbiome through adding or eradicating bacteria. It also has a GI tract cancer program in prototype discovery and a checkpoint inhibitor program in target discovery.
- Jan 2026Post IPO$3.3M
- Feb 2025Post IPO$12M
- Mar 2024Post IPO$50M
- Mar 2023Post IPO$1.5M
#2
Series C · Tel Aviv, Tel Aviv · founded 2017$25Mraised▾
Developer of a non-invasive glucometer device for diabetes patients. The company's device utilizes radiofrequency waves to continuously measure glucose levels in the blood. The device is integrated with a smartphone application to track glucose readings.
- Aug 2023Series C$5M
- Aug 2021Series B$11.7M
- Mar 2021Series A$4.4M
#3
Public · Jerusalem, Jerusalem District · founded 2006 · 17 employees$22.6Mraised▾
Developer of oral reformulations to treat various health conditions. Its proprietary platform POD(Protein Oral Delivery) technology protects proteins from an enzymatic breakdown in the GI tract while increasing bioabsorption across the intestinal wall. The product pipeline includes ORMD-0801 for type-2 and type-1 diabetes. In addition, the company has another candidate that is an oral formulation Exenatide, a glucagon-like peptide-1 analog that stimulates insulin secretion.
- Mar 2020Grant (prize money)$55.3K
- Dec 2019Grant (prize money)$55.1K
- Jul 2018Post IPO$18.1M
- Jan 2013Post IPO$76.4K
#4
Seed · Jerusalem, Jerusalem District · founded 2017 · 16 employees$4.8Mraised▾
AI-based device and platform for diagnosing diabetic patient feet. The device uses infrared and near-infrared light to screen the feet for wounds, infection, and foot ischemia in the diabetic foot. The data is recorded on the cloud platform and assessed using proprietary algorithms. The AI and ML technology provide 3-dimensional maps describing physiological parameters within the foot and provide the prognosis. The disease is monitored for progress in treatment and also the data can be shared with the doctors.
- Apr 2023Seed$2.3M
- Jun 2021Seed$2.5M
- Aug 2019Grant (prize money)$55.4K
- May 2017Seed—
#5
Deadpooled · Lod, Central District · founded 2007 · 6 employees$26.9Mraised▾
GluSense is developing a long-term implantable continuous glucose sensor (CGM) for Type 1 Diabetes Mellitus patients. Its technology is based on a fluorescent protein which reports the level of glucose. Long term operation is achieved using engineered live cells which are encapsulated within the device and continuously produce the fluorescent protein. These genetically-engineered human cells colored red and blue move into different patterns depending on the amount of glucose in the blood. It is a portfolio company of Rainbow Medical.
- Feb 2017Series A$1.9M
- Feb 2015Series A$25M
#6
Series A · Ramat Gan, Tel Aviv District · founded 2015 · 9 employees$6Mraised▾
Developer of a micro-pancreas for diabetes treatment. This technology uses stem cell technology and tissue engineering to create a functional micro-pancreas that regulates insulin release based on blood glucose levels. The micro-pancreas is designed to improve insulin production, reduce cell mortality, and offer a less invasive implantation procedure compared to existing treatments. It aims to provide a long-term solution for managing diabetes by restoring beta-cell mass and eliminating the need for daily insulin injections.
- Jul 2021Series A—
- Sep 2020Grant (prize money)$2.9M
- Mar 2020Grant (prize money)$1.4M
- Oct 2019Series A$3.5M
#7
Deadpooled · Kfar Saba, Central District · founded 2003 · 7 employees$20Mraised▾
MetaCure develops implantable devices for the treatment of Type 2 (adult) diabetes. Their key product, Diamond (Tantalus) is implanted under the abdominal skin in a one-time surgery. The small implanted DIAMOND device detects when eating begins, and automatically sends gentle pulse signals (gastric contractility modulation signals, or GCM) to the stomach muscles. As a result, the DIAMOND restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels. Additionally, GCM signals cause an earlier satiation effect resulting in sustained weight loss. The external device is used to charge the implanted device wirelessly once a week by the patient at home. It can be used for up to 15 years before a replacement is needed.. As of July 2016, Diamond-I has received CE mark and is approved for sale in Europe, Australia and other international markets. It is not approved for use in the USA. Metacure's offices are located in Hamilton, New York, Stuttgart and Sydney. The company is backed by the Hobart Group.
- Apr 2009Series B$20M
#8
Funding Raised · Herzliya, Tel Aviv · founded 2016 · 8 employees$749.8Kraised▾
QuLab Medical is developing a minimally-invasive continuous glucose monitoring system. The company has developed a patch that continuously measures the metabolic parameters of the blood. The company is using proprietary silicon nano-sensor technology, MEMS and data science to develop microneedles based implant and provide insights using metabolic profiles.
- Feb 2023Grant (prize money)$749.8K
#9
Series B · Herzliya Pituach, Israel · founded 2013 · 14 employees$4Mraised▾
SmartZyme is using Provolution, a proprietary technological platform for protein design and engineering. It aims to efficiently design and create proteins and potent enzymes with the specific characteristics required for optimal performance. It is currently focusing on the diabetes market where it intends to launch its first two products: a pre-designed enzyme with superior characteristics for improved bio-electrochemical glucose catalysis, to be used on glucose test strips for the Self Monitoring Blood Glucose (SMBG) market. The company’s second product, the Go Patch Go, personalized patient care system (PCS), an on-demand blood glucose measurement system.
#10
Series A · Rosh Haayin, Center District · founded 2004 · 17 employees$2Mraised▾
Beta - O2 has developed a proprietary bio-artificial pancreas. The beta-Air device contains living cells that are responsive to glucose levels in the blood, and release insulin accordingly. The device is implantable and requires no immunosuppressive therapy.
- Feb 2015Series A—
- Oct 2014Series A—
- Sep 2014Grant (prize money)$500K
- Mar 2004Seed$2M
#11
Funding Raised · Caesarea, Haifa District · founded 2014$116.3Kraised▾
Allevetix develops a device for controlling gut hormone balance in the body for treating type 2 diabetes. The company includes a gastric sleeve placed in the duodenal section of the small intestine and a unique patented sleeve anchor that is positioned in the stomach. The sleeves function is to stabilize the gut hormones in the body.
- Sep 2018Grant (prize money)$58K
- Jun 2018Grant (prize money)$58.3K
#12
Deadpooled · Hofit, Center District · founded 2015$120.7Kraised▾
Insulog is a patented insulin tracking device that can be added to a disposable insulin pen to display the last intake and record them on the smartphone. It claims that the device automatically detects the amount of insulin administered & syncs the data to the app connected via Bluetooth. The user can review the data and can even easily share it with the medical team. It claims that the device is compatible with all major insulin pen brands & can be charged via micro-USB. The device was featured on Indiegogo. In Mar 2017, the company was one of the winners at the inauguration event of the eHealth Ventures incubator, a digital health incubator in Israel.
- Apr 2018Grant (prize money)$60.6K
- Jan 2018Grant (prize money)$60.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.